Grant Archive - Page 63 of 138

Elda Grabocka, Ph.D.

Funded in memory of Patty Molloy.

Pancreatic cancer is one of the most lethal cancers and has a five-year survival rate of ~9%. This outcome is largely due to limitations in current diagnostic strategies as well a lack of eﬀective therapies. Thus, there is a dire need to better understand this disease. Recent studies in cancer research have indicated a causal relationship between the capacity of cancer cells to cope with stress and cancer progression and therapy resistance. Pancreatic tumors are driven by a gene called KRAS that is mutated in 95% of all human pancreatic cancers. We have recently found that one critical process driven by mutant KRAS is the formation of stress granules. Stress granules serve as a protective mechanism from chemotherapeutic agents, which kill cancer cells by inducing stress. In this proposal, my laboratory will determine the role of stress granules in the drug resistance of KRAS-driven pancreatic cancer, and develop strategies to block stress granules as a therapeutic tool. This approach has not been explored and could provide impactful insight for the treatment of this disease.

Francine Garrett-Bakelman, Ph.D, M.D.

Funded by the Stuart Scott Memorial Cancer Research Fund

Acute Myeloid Leukemia (AML) is a blood cancer that affects individuals of all ages. AML is the most common form of acute leukemia in adults. The incidence of the disease increases with age, with the majority of patients being diagnosed over the age of sixty. With aging, the disease does not respond as readily to treatments. Despite advances in the field, clinical outcomes for AML patients over the age of sixty remain poor. To improve upon current treatment options for AML patients over the age of sixty, it is essential to better understand the mechanisms that drive the disease in these patients and determine which patients benefit from current treatments. The project proposed will identify molecular features that characterize patients over the age of sixty and determine how to predict which patients benefit from current treatments and what potential mechanisms drive the disease in individuals over the age of sixty.

Mohammad Fallahi-Sichani, Ph.D.

Tumor cells carrying driver oncogenes such as mutated BRAF, EGFR and EML4-ALK appear to sustain an oncogene addiction state, in which growth and survival are highly dependent on the continued activity of the oncogenic pathway. The discovery of such dependencies has informed drug development strategies for a variety of cancers. However, patient responses to therapeutic inhibitors of oncogene action are often incomplete and limited by drug resistance. Although genetic factors in resistance are part of the story, emerging evidence suggests that tissue-specific epigenetic mechanisms and reprograming following oncogene inhibition can induce adapted states where there is reduced dependence on the oncogenic activity. These epigenetic states generate heterogeneous sub-populations of drug-tolerant cells that not only limit drug effectiveness, but also constitute a reservoir from which genetically resistant clones are ultimately selected and contribute to disease progression. This represents a major challenge facing development and use of targeted therapies for a variety of cancers. Our research aims at addressing this problem for BRAF-mutant tumors. We are proposing an integrated strategy to dissect the poorly understood epigenetic states at the single-cell level, identify their key regulators, and predict and test efficient ways to block the heterogeneous populations of drug-resistant cells and maximize tumor cell killing. Our findings will help us utilize targeted therapeutics more generally, more precisely, and more effectively to cure cancer.

Nadya Dimitrova, Ph.D.

First year of this grant was funded in part by UNICO, in memory of Carl Esposito

Lung cancer is the leading cause of cancer deaths worldwide in men and women, with adenocarcinoma being the most prevalent subtype of non-cell lung cancer in the US. The National Cancer Institute estimates that, in 2016 alone, over 220,000 Americans were diagnosed with lung cancer and close to 160,000 Americans died of their disease. These dismal numbers have not changed significantly over the past decade. Thus, despite enormous advances in our understanding of many of the genetic, epigenetic, and immune events that underlie lung cancer development, a vast amount of knowledge remains to be amassed in order to improve human health. The experiments outlined in this proposal aim to elucidate how an understudied class of genes, called long noncoding RNAs (lncRNAs), participates in lung cancer development and may be harnessed for therapeutic applications. Specifically, we propose innovative approaches to investigate a set of lncRNAs downstream of the key tumor suppressor protein p53. By selecting this pathway, our intent is to dissect a molecular network, which represents a known barrier to lung adenocarcinoma progression, allowing us to discover and characterize lncRNAs that may modulate the transition to advanced and metastatic disease. Our ultimate goal is two-fold – first, to open new avenues in how we explore the significance of lncRNAs in disease states, such as lung cancer, for which few effective treatment options exist, and second, to make the first strides towards deciphering the regulatory code of lncRNAs, thus expanding the druggable space in cancer and ultimately improving patient outcomes.

Gina DeNicola, Ph.D.

Lung cancer accounts for the largest number of cancer deaths for both men and women. While there have been recent advances in treatment options for patients having lung tumors that have specific mutations, or by harnessing patients own immune systems, the vast majority of patients with advanced tumors will not respond to these treatments or they will relapse following an initial response. A common feature of lung tumors is their increased production of antioxidants, which promote their growth and survival and which contribute to resistance to therapies. The DeNicola lab studies how the production of antioxidants by lung tumor cells affects these processes, and how blocking antioxidant production inhibits tumor formation and progression.

We recently found that many lung tumors increase their levels of an antioxidant protein called NNT, which was not previously associated with lung cancer. Notably, studies of the DeNicola lab show that if NNT is not present, lung tumors cannot form. In these V Foundation Scholar studies, we will define how NNT is regulated in lung cancer cells, and will develop strategies to block the function of NNT.  In addition, we seek to understand how NNT promotes tumor formation. These studies will provide an improved understanding of NNT, and will allow us to design better therapies for lung cancers that have increased NNT levels.

John Cunningham, Ph.D.

Nucleotides are the building blocks of our genetic material and must be replicated every time a cell divides. Chemotherapeutic drugs interfering with nucleotide metabolism exploit this requirement and are a valuable weapon in the oncologist’s arsenal. However, the cytotoxic properties which make these compounds so efficacious in killing cancer cells also wreak havoc on normal proliferating cells and tissues. In order to create the next generation of drugs that inhibit nucleotide metabolism, we must identify novel targets that are specifically required by cancer cell, but not normal cell, proliferation and survival. My discoveries have identified one such target – the enzyme phosphoribosyl pyrophosphate synthetase 2 (PRPS2). PRPS2, and its paralog PRPS1, generate a critical precursor necessary for producing all nucleotides and function as a ‘molecular throttle’ capable of increasing or decreasing the rate at which these genetic building blocks are made. While targeting this metabolic enzyme represents a powerful approach to stymie nucleotide production, the redundancy afforded by the existence of two distinct forms of the same enzyme also presents a phenomenal opportunity for selectively killing cancer cells. In line with this, I have demonstrated that PRPS2, but not PRPS1, is specifically upregulated and required by cancer cells. This is in contrast to normal cells and developing organisms which require PRPS1, but not PRPS2. This proposal seeks to unravel the molecular basis for this selectivity through use of novel mouse models and structure/function studies, thus pinpointing a putative mechanism of action and developing a rational basis for future drug development.

Stephanie Correa, Ph.D.

Funded by the Stuart Scott Memorial Cancer Research Fund

Tamoxifen is an estrogen-like drug that is used to treat breast cancer patients, breast cancer survivors, and patients with a family history of breast cancer. As a treatment, tamoxifen is extremely effective at decreasing the changes of getting cancer and increasing patient survival. Unfortunately, tamoxifen also causes negative side effects such as hot flashes and bone loss. Because of these concerns, up to a quarter of all patients fail to complete the treatment. The goal of our research is to understand how tamoxifen can cause hot flashes and bone loss. We will use genetically engineered mice to identify the brain regions that mediate the effects of tamoxifen on temperature control and bone density. We will also use cutting-edge molecular tools to determine precisely how these brain regions are affected by tamoxifen. To model the treatment conditions in humans, our studies use females of reproductive age and a long-term treatment using the same dosage given to humans. In the end, our studies will identify the specific areas that are responsible for the negative effects of tamoxifen. This information will help us design and begin to test strategies for alleviating hot flashes and/or bone loss in patients. Any treatments that provide relief from the side effects of tamoxifen will increase patient quality of life, increase the chances that patients will complete their treatments, and ultimately save lives.

Kevin Cheung, M.D.

Funded by Hooters of America, LLC

Metastatic breast cancer is a result of breast cancer cells that spread to and grow in other organs. It is one of the most feared consequences of breast cancer, and the main cause of death from this disease. Yet, we still do not know what causes breast cancer cells to spread and become resistant to cancer treatment. For years, researchers have attempted to learn what makes individual cancer cells within tumors most able to migrate and grow elsewhere. My lab recently found that the cells that are the most successful at metastasizing do so as clusters. Clusters are also more resistant to cancer treatment. In this project, we will evaluate the different ways that tumor cells within these clusters communicate with each other. By studying these signals, how they are transmitted and their consequences, we may uncover the key vulnerabilities needed to disrupt and destroy tumor cell clusters. We will take advantage of a technology we invented that allows us to study ‘mini-tumors’ in a dish. We will also analyze the genetic code of the various cell types in the mini-tumors. We will then cross-reference what we learn with very large studies of breast cancer patients. Through shifting our mindset from the individual to the collective, our ultimate goal is to identify new leads for the development of therapies to treat – or prevent- metastasis so that we can save lives.

Sidi Chen, Ph.D.

Funded by the Dick Vitale Gala in memory of John Saunders

My research team is developing and applying novel tools for genetics, genomics and systems biology to tackle fundamental problems in cancer biology and therapeutics. In this project, we will focus on childhood cancer, the leading disease-related cause of death among children in the United States. Better treatments for these types of cancer will thus deeply benefit children. Developing such treatments will require addressing the highly complex and heterogeneous nature of cancer, for any given tumor can contain an enormous repertoire of genetic mutations within it that can also change over time. Understanding the roles of cancer genes has been hampered by the lack of large-scale methods to directly identify and interrogate the function of large numbers of genes in vivo. My goal is to invent such a platform, which will allow simultaneous mapping of the effects of many genes on cancer progression and therapeutic responses. The platform will combine genome editing, synthetic biology, in vivo animal models, high-throughput genetic screening and high-performance computing. I will develop this platform and apply it to study both solid tumors and liquid cancers diagnosed in children. I will first use it to perform large-scale in vivo genetic analysis in medulloblastoma to reveal the global genetic landscape of the progression of this disease. This analysis will also discover important driver genes, providing knowledge for more precise diagnostics and prognoses, and potentially better therapeutic strategies. Discovery of such targets will ultimately lead to improved therapeutics to save many children’s lives from childhood cancer.

Christine Brainson, Ph.D.

2017 V Foundation Wine Celebration Volunteer Grant in honor of Susan Leick and Joe McCrary

Lung cancer is the leading cause of cancer-related deaths worldwide, and is a very complex disease with different cell types that make up each tumor.  Immunotherapy is ground-breaking because it is able to cure some patients with late stage tumors.  However, the number of patients that have this great response is still low. In this proposal, we will test the combination of a second drug with immunotherapy to increase the likelihood that squamous lung tumors will respond to treatment.  To do this, we will use two mouse models of squamous cell carcinoma.  These models are ideal for testing immunotherapy because they have intact immune systems and have many features of the human disease.  We will test whether the second therapy changes the cell types that make up the tumor, and whether these changes lead to better therapy outcomes.  If our results show that the second drug can boost the immunotherapy, we can rapidly transition this work to clinical trials in human lung cancer patients.